Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colestilan in Pediatric CKD with Hyperphosphatemia
NCT01818687Phase 3Terminated
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Aug 2013
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of colestilan in hyperphosphatemia, sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Percentage of subjects who, due to hyperphosphataemia, require rescue treatment and/or discontinuation of therapy with colestilan at 17 weeks. Started Aug 2013; status: terminated.
02
Drugs
colestilan
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT01818687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01818687.